Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Denosumab in postmenopausal women with osteoporosis and diabetes

Key clinical point: Women with osteoporosis and diabetes who were treated with densoumab had continued increases in bone mineral density, reduced vertebral fracture rates, and overall low, long-term fracture incidence.

Major finding: Women receiving denosumab had significantly lower new vertebral fracture rates, compared with placebo (1.6% vs. 8.0%; relative risk, 0.20; 95% confidence interval, 0.07–0.61; P = .001).

Study details: Post hoc analysis of the 3-year, placebo-controlled FREEDOM study and 7-year extension of 508

postmenopausal women with osteoporosis and diabetes, of whom 266 received denosumab and 242, placebo.

Disclosures: Amgen funded the study, and three authors are Amgen employees with stock options. The remaining authors have relationships with Amgen and other drug companies, all outside the submitted work.

Citation:

Ferrari S et al. Bone. 2020 Feb 10.